Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 10/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28431371 | 0.92 | CA1 (0.41) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL25595219 | 0.92 | CA1 (0.41) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL1318739 | 0.92 | CA1 (0.41) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL1318743 | 0.92 | CA1 (0.41) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL1552190 | 0.92 | CA1 (0.41) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL1318741 | 0.92 | CA1 (0.41) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL13248858 | 0.87 | AAK1 (0.49) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL3049361 | 0.87 | AAK1 (0.49) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL3049887 | 0.87 | AAK1 (0.49) | CA1CA7CA2AAK1CTSK | |
| SCHEMBL14910269 | 0.87 | SYK (0.43) | CA1CA7CA2CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157492-A1 | ANTIBIOTIC DRUG | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157492-A1 | ANTIBIOTIC DRUG | MAL2, ME1, ACE | CA1 2015/4885CA7 61/4885CA2 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.